ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MEDG Medgenics(Regs)

302.50
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Medgenics(Regs) LSE:MEDG London Ordinary Share COM SHS USD0.0001 (REGS)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 302.50 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Medgenics Inc Purchase of Common Stock by Director (8468V)

18/12/2013 1:30pm

UK Regulatory


Medgenics(Regs) (LSE:MEDG)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Medgenics(Regs) Charts.

TIDMMEDG TIDMMEDU

RNS Number : 8468V

Medgenics Inc

18 December 2013

 
 Press Release   18 December 2013 
 

Medgenics Reports Open Market Purchase of Common Stock by Director

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), ("the Company"), the developer of Biopump(TM) , a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that the Company was informed today by Dr. Alastair Clemow, a director of the Company, that he purchased 4,500 shares of common stock on the open market on 16 December at an average price of $5.7787 per share.

Following this purchase, Dr. Clemow now owns 18,500 shares of common stock, which represents approximately 0.1 per cent of the total issued shares of common stock. Dr. Clemow also has the right to purchase up to 105,714 shares of common stock pursuant to options previously granted (in aggregate Dr. Clemow's shares of common stock and options represent 124,214 shares of common stock which represent approximately 0.7 per cent of the Company's total issued shares of common stock).

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

About Medgenics

Medgenics is developing and commercializing Biopump(TM), a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others. For more information, please visit www.medgenics.com.

Contacts:

 
 Medgenics, Inc. 
  John Leaman, CFO 
  john.leaman@medgenics.com 
 
  LHA 
  Anne Marie Fields 
  212-838-3777 
  afields@lhai.com 
  @LHA_IR_PR 
 Abchurch Communications 
  Joanne Shears / Jamie Hooper 
  / Harriet Rae 
  harriet.rae@abchurch-group.com      +44 207 398 7718 
 Oriel Securities (NOMAD & Broker) 
  Jonathan Senior / Giles Balleny     +44 207 710 7617 
 

- Ends-

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSEANAPFEFDFEF

1 Year Medgenics(Regs) Chart

1 Year Medgenics(Regs) Chart

1 Month Medgenics(Regs) Chart

1 Month Medgenics(Regs) Chart